Holen Sie sich die Stockscreener-App
305.05
0.44%
1.34
Handel nachbörslich:
305.05
Schlusskurs vom Vortag:
$303.71
Offen:
$298.87
24-Stunden-Volumen:
134.18K
Relative Volume:
0.54
Marktkapitalisierung:
$6.71B
Einnahmen:
$2.58B
Nettoeinkommen (Verlust:
$-778.69M
KGV:
-11.16
EPS:
-27.33
Netto-Cashflow:
$223.75M
1W Leistung:
+2.88%
1M Leistung:
+8.81%
6M Leistung:
+22.21%
1J Leistung:
-10.56%
1-Tages-Spanne:
$298.87
$309.59
1-Wochen-Bereich:
$292.56
$309.59
52-Wochen-Spanne:
$211.43
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Vergleichen Sie BIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
305.05 | 8.22B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
133.27 | 228.66B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
96.24 | 140.69B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
370.00 | 139.51B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
96.54 | 122.60B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.36 | 42.83B | 5.69B | 1.41B | 577.90M | 6.9828 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Bio-Rad Q2 2025 presentation: Life Science growth offsets diagnostics slowdown - Investing.com UK
Earnings call transcript: Bio-Rad Labs Q2 2025 shows steady growth - Investing.com Canada
Top chart patterns to watch in Bio Rad Laboratories Inc.2025 Volume Leaders & Community Consensus Trade Signals - newser.com
Does Bio Rad Laboratories Inc. qualify in momentum factor screeningMarket Risk Summary & Community Consensus Picks - newser.com
Bio-Rad To Distribute Gencurix Digital PCR Cancer Tests - Technology Networks
How to build a custom watchlist for Bio Rad Laboratories Inc.Earnings Risk Summary & Precise Entry and Exit Recommendations - newser.com
Using Bollinger Bands to evaluate Bio Rad Laboratories Inc.July 2025 PreEarnings & AI Enhanced Trading Alerts - newser.com
Is Bio Rad Laboratories Inc. stock a bargain at current levelsGlobal Markets & Reliable Intraday Trade Plans - newser.com
Is Bio Rad Laboratories Inc. (BUWA) stock protected from inflationJuly 2025 Chart Watch & Verified Momentum Watchlists - newser.com
Is Bio Rad Laboratories Inc. a candidate for recovery playPortfolio Value Summary & Consistent Income Trade Recommendations - newser.com
Why ETFs are accumulating Bio Rad Laboratories Inc. Class B stockEarnings Recap Summary & Expert Verified Stock Movement Alerts - newser.com
How strong is Bio Rad Laboratories Inc. stock balance sheetEarnings Risk Summary & Smart Investment Allocation Insights - newser.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Insights into a Healthcare Pioneer with 4.12% Upside Potential - DirectorsTalk Interviews
Hydroxyapatite Market to Witness Significant Growth from 2025 - openPR.com
Bio-Rad offers to acquire digital PCR developer Stilla Technologies - MSN
How buyback programs support Bio Rad Laboratories Inc. Class B stockJuly 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - newser.com
What institutional flow reveals about Bio Rad Laboratories Inc.Trade Exit Summary & High Return Trade Opportunity Guides - newser.com
Sivik Global Healthcare LLC Makes New Investment in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Can Bio Rad Laboratories Inc. (BUW) stock resist broad market declinesJuly 2025 Sentiment & Long-Term Safe Investment Plans - newser.com
Bio-Rad Laboratories (NYSE:BIO.B) Stock Price Up 15.3%Here's What Happened - MarketBeat
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap UpWhat's Next? - MarketBeat
Bio-Rad Laboratories, Inc. $BIO Shares Sold by DAVENPORT & Co LLC - MarketBeat
KnowItAll Spectroscopy Software | Bio-Rad Laboratories Inc., Informatics Div. | New Products - Photonics Spectra
Will Bio Rad Laboratories Inc. (BUW) stock gain from lower interest ratesOil Prices & Reliable Entry Point Trade Alerts - newser.com
Can technical indicators confirm Bio Rad Laboratories Inc.’s reversalAnalyst Downgrade & Expert Curated Trade Ideas - newser.com
Will Bio Rad Laboratories Inc. see short term momentumJuly 2025 Highlights & Low Risk Entry Point Tips - newser.com
Newborn Screening Market Huge Growth in Future Scope 2025-2032 | Agilent Technologies, Inc., Bio-rad laboratories, Inc. - industrytoday.co.uk
Published on: 2025-10-10 05:39:23 - newser.com
Why Bio Rad Laboratories Inc. stock is favored by pension funds2025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com
Market reaction to Bio Rad Laboratories Inc.’s recent newsPortfolio Update Summary & Weekly High Return Stock Opportunities - newser.com
945 Shares in Bio-Rad Laboratories, Inc. $BIO Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
Will Bio Rad Laboratories Inc. Class stock outperform value peers2025 Sector Review & High Yield Stock Recommendations - newser.com
Why Bio Rad Laboratories Inc. Class B stock is a strong analyst pickWeekly Volume Report & AI Powered Market Entry Ideas - newser.com
Published on: 2025-10-09 05:47:16 - newser.com
Is Bio Rad Laboratories Inc. (BUWA) stock nearing a technical breakoutPortfolio Value Report & Free Accurate Trade Setup Notifications - newser.com
Bio-Rad Extends Partnership with Gencurix Through Strategic Agreement for Droplet Digital PCR IVD Oncology Kits in Europe - the-scientist.com
Future of Polymerase Chain Reaction (PCR) Market Growth - openPR.com
Liquid Handling Systems Market Size, Scope 2032 by Key - openPR.com
Exploring the Potential of Chromatography Resins in Therapeutic Treatment Delivery - BioProcess International
Real-Time PCR And Digital PCR Market Size, Trends Analysis 2032 - openPR.com
United States Next Generation Sequencing Market Size, Trends & - openPR.com
A Look at Bio-Rad Laboratories’s Valuation Following Precision Medicine Push and New ddPCR Platform Launches - Sahm
Life Sciences Tools Market Size, Dynamics 2031 by Major - openPR.com
How Bio Rad Laboratories Inc. Class stock trades pre earningsJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - newser.com
Why Bio Rad Laboratories Inc. (BUW) stock stays resilientMarket Weekly Review & High Conviction Buy Zone Picks - newser.com
What market sentiment indicators show for Bio Rad Laboratories Inc. (BUWA) stock2025 EndofYear Setup & Proven Capital Preservation Methods - newser.com
Is Bio Rad Laboratories Inc. Class stock a top dividend aristocrat candidateBond Market & Safe Capital Growth Tips - newser.com
Why Bio Rad Laboratories Inc. Class B stock appears on watchlistsJuly 2025 PreEarnings & Verified Swing Trading Watchlists - newser.com
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
1.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):